Protocol for systematic review and meta-analysis for randomized clinical trials on patiromer efficacy and safety in subjects with heart failure.
Background: We shall assess the efficacy and safety of patiromer in subjects with heart failure (HF) in randomized controlled trials (RCTs). Methods: The protocol has been developed supported the PRISMA-P checklist by using (PICO [population, intervention, comparators, and outcome]) items, for adult...
| Publicado en: | Pharmacy Practice (1886-3655) Vol. 22; no. 2; pp. 1 - 14 |
|---|---|
| Autores principales: | , |
| Formato: | protocol tables/charts Journal Article |
| Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas S.L.
Apr-Jun2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178612462&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178612462 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1885642X 3EAU jtl: Pharmacy Practice (1886-3655) issn: 1885642X maglogo: N pubinfo: dt: Apr-Jun2024 vid: 22 iid: 2 pid: 36266 pub: Centro de Investigaciones y Publicaciones Farmaceuticas S.L. artinfo: ui: 178612462 178612462 178612462 10.18549/PharmPract.2024.2.2714 178612462 ppf: 1 ppct: 13 formats: fmt: @attributes: type: P tig: atl: Protocol for systematic review and meta-analysis for randomized clinical trials on patiromer efficacy and safety in subjects with heart failure. aug: au: Elnour, Asim Ahmed Shehab, Abdulla affil: Program of Clinical Pharmacy, College of Pharmacy, Al Ain University-Abu Dhabi campus, Abu Dhabi-UAE sug: subj: Heart Failure Drug Therapy Polymers Therapeutic Use Chelating Agents Therapeutic Use Cardiotonic Agents Therapeutic Use Drug Efficacy Patient Safety Systematic Review Meta Analysis ab: Background: We shall assess the efficacy and safety of patiromer in subjects with heart failure (HF) in randomized controlled trials (RCTs). Methods: The protocol has been developed supported the PRISMA-P checklist by using (PICO [population, intervention, comparators, and outcome]) items, for adult subjects with HF who have received patiromer in RCTs versus SZC or placebo to attain specific endpoint of control of hyperkalemia. The subjects with HF (population) receiving patiromer (intervention) are compared to placebo or other potassium binders (comparators), like sodium zirconium cyclosilicate (ZS-9, SZC, Lokelma®) for the non-inferiority or superiority in terms of effects on hyperkalemia (outcome) and alter in potassium serum levels. Results: Patiromer may provide an efficient treatment for hyperkalemia in subjects with HF receiving angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) and/or mineralocorticoids/aldosterone antagonists (MRA/AA). Patiromer may facilitate the clinical utility of RAAS inhibitors without discontinuation or interruption of therapy in subjects with HF. Patiromer may enable dose titration of AA without the danger of hyperkalemia. Patiromer is anticipated to halt recurrence of hyperkalemia in subjects with HF. Conclusion: Patiromer may provide safe and effective therapy for prevention, maintenance, management, and prevent recurrence of hyperkalemia in subjects with HF as compared to the other comparators. pubtype: Academic Journal doctype: protocol tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|